Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights –

The “Parkinson’s
Disease Market: Pipeline Review, Developer Landscape and Competitive
Insights” report has been added to’s

Parkinson’s disease is a chronic disorder that gradually leads to
progressive deterioration of motor functions due to loss of
dopamine-producing brain cells. It is presently the second most common
neurodegenerative disease (after Alzheimer’s disease) and is
characterized by symptoms such as shaking, rigidity, difficulty in
walking / movement, and several other cognitive and behavioral problems.
Parkinson’s disease is known to affect 1-2 per 1,000 individuals and has
been shown to impact approximately 1% of the population aged above 60
years. It is also worth highlighting that, every year, nearly 60,000
Americans are diagnosed with Parkinson’s.

The disease has been estimated to incur combined direct and indirect
costs of close to USD 25 billion in the US annually. With increasing
disease prevalence and the corresponding growth in socioeconomic burden,
the field faces a pressing need for accurate diagnostic (predictive)
tests, and efficient treatment options for slowing the progression of
the disease.

The unavailability of neuroprotective therapies remains one of the prime
unmet needs in this domain. The disease is highly complex and is known
to render any single therapeutic approach inadequate to deal with its
multifaceted etiopathogenesis. Currently, several stakeholders in the
pharmaceutical industry are engaged in efforts to advance the
development of various types of disease modifying pharmacological
interventions, therapies to offer symptomatic relief and drugs to try to
cure the disease as well.

Companies Mentioned:

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Pipeline Review: Marketed And Development Drugs

5. Parkinson’s Disease: UNMET Need Analysis

6. Drug Profiles: Phase III Molecules

7. Company Competitiveness Analysis

8. Mergers And Acquisitions

9. Kol Analysis

10. Funding And Investment Analysis

11. Survey Analysis

12. Appendix 1: Tabulated Data

13. Appendix 2: List Of Companies And Organizations

For more information about this report visit

View source version on

Leave a Comment